1h Free Analyst Time
According to the recently published report 'Leptin Receptor - Drugs In Development, 2022'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 10 molecules.Speak directly to the analyst to clarify any post sales queries you may have.
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.
The report 'Leptin Receptor - Drugs In Development, 2022' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 8 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Non Malignant Disorders which include indications Obesity, Lipodystrophy (Lipoatrophy), Triple-Negative Breast Cancer (TNBC), Acquired Generalized Lipodystrophy (Lawrence Syndrome), Alzheimer's Disease, Benign Tumor, Choroidal Neovascularization, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome), Insulin Resistance, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes and Unspecified Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
- The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview
- Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development
- Aceragen Inc
- Amryt Pharma Plc
- Astellas Pharma Inc
- Cellivery Therapeutics Inc
- Jyant Technologies Inc
- NeuroNano Pharma Inc
- Neurotez Inc
- Regeneron Pharmaceuticals Inc
- XL-protein GmbH
- Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles
- ACG-401 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CV-08 - Drug Profile
- Product Description
- Mechanism Of Action
- memtin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- metreleptin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mibavademab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Peptides to Antagonize LEPR for Triple-Negative Breast Cancer - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VET-2L2 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- XL-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products
- Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products
- Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Aceragen Inc, 2022
- Pipeline by Amryt Pharma Plc, 2022
- Pipeline by Astellas Pharma Inc, 2022
- Pipeline by Cellivery Therapeutics Inc, 2022
- Pipeline by Jyant Technologies Inc, 2022
- Pipeline by NeuroNano Pharma Inc, 2022
- Pipeline by Neurotez Inc, 2022
- Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Pipeline by XL-protein GmbH, 2022
- Dormant Projects, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aceragen Inc
- Amryt Pharma Plc
- Astellas Pharma Inc
- Cellivery Therapeutics Inc
- Jyant Technologies Inc
- NeuroNano Pharma Inc
- Neurotez Inc
- Regeneron Pharmaceuticals Inc
- XL-protein GmbH
